Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NOVATO, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on March 15, 2013, the compensation committee of BioMarin's board of directors...
March 18, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Completes Partial Exchange of Convertible Notes Due 2017 for Common Stock

SAN RAFAEL, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that seven holders of its 1.875% Convertible Senior Subordinated Notes due 2017 have...
February 28, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Attend Upcoming Conferences: Cowen Healthcare Conference, Credit Suisse Global Healthcare Conference and Barclays Global Healthcare Conference

SAN RAFAEL, Calif., Feb. 28, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that BioMarin will attend the Cowen Healthcare Conference in Boston on March 4th, the...
February 21, 2013 16:03 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Fourth Quarter and Full Year 2012 Financial Results

Total Revenue in 2012 Exceeds $500 Million PEG-PAL End of Phase 2 Meeting Completed, Phase 3 to Begin Next Quarter Conference Call and Webcast to Be Held Today at 5:00 p.m. ET Financial...
February 21, 2013 16:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Licenses Factor VIII Gene Therapy Program for Hemophilia A From University College London and St. Jude Children's Research Hospital

SAN RAFAEL, Calif., Feb. 21, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has licensed a Factor VIII gene therapy program for hemophilia A from...
February 20, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SAN RAFAEL, Calif., Feb. 20, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on February 15, 2013, the compensation committee of BioMarin's board of directors...
February 19, 2013 16:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Attend Upcoming Conferences: Canaccord Genuity Orphan Drug Day, Citibank Global Healthcare Conference and RBC Capital Markets Healthcare Conference

SAN RAFAEL, Calif., Feb. 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that BioMarin will attend the Canaccord Genuity Orphan Drug Day on February 25th, the...
February 19, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Kuvan Significantly Improves Inattentiveness in Kuvan Responding PKU Patients

SAN RAFAEL, Calif., Feb. 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today results from the PKU-016 ASCEND study, the largest randomized controlled trial...
February 11, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

Presentations at WORLD Symposium: Vimizim Phase 3 Results and BMN-701 Phase 1/2 Patient Demographics

SAN RAFAEL, Calif., Feb. 11, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the following presentations will be featured at the 9th Annual WORLD Symposium in...
February 06, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Present at the BIO CEO & Investor Conference

SAN RAFAEL, Calif., Feb. 6, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer at BioMarin, will present a...